Visual Abstract
Background: This study presents real-world evidence on effectiveness of sema OW in a broad cohort of US commercially insured and Medicare Advantage T2D patients.
Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. Patients persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c measurement) were assessed for A1c changes and stratified by age (</≥ 65 years) and those with pre-index A1c >9%.
Results: 3,010 patients initiated sema OW, 49% were female and 10% were ≥ 65 years of age. A1c was significantly reduced vs. pre-index in all persistent patients (-1.1%) and in each age subgroup (<65 years = -1.1%; ≥ 65 years = -0.9%; all p<0.001, Figure 1). Regardless of age subgroup, A1c reductions of ≥ 2.0% were observed in patients with pre-index A1c >9%. Attainment of A1c <7% and <8% increased from 23% to 52% and from 50% pre-to 79% post-index for all patients, respectively (both p<0.001).
Conclusion: In this broad, real-world cohort of US T2D patients, initiation of sema OW was associated with significant reduction in A1c and an increase in reaching an A1c <7% and <8% in both age groups. Those with an baseline A1c ≥9% had the greatest reduction.
V. Willey: Employee; Self; HealthCore. N. Shivappa: Other Relationship; Self; Novo Nordisk. J. Noone: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. S. Du: None. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. H. Tan: Other Relationship; Self; HealthCore.
